Scynexis Inc (SCYX)

$0.78 -0.04 (-5.35%)
Market Cap 36.81M
Revenue (ttm) 20.60M
Net Income (ttm) -8.61M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -41.80%
Debt to Equity Ratio 0.00
Volume 535,200
Avg Vol 601,284
Day's Range N/A - N/A
Shares Out 44.66M
Stochastic %K 17%
Beta 1.12
Analysts Strong Sell
Price Target $4.19

Company Profile

SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fungal infections. The company was formerly known as SCYNEXIS Chemistry & Automati...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 201 884 5485
Address:
1 Evertrust Plaza, 13th Floor, Jersey City, United States
intheriver
intheriver May. 12 at 4:42 PM
$SCYX I don’t understand the basis of executive compensation. They appear to have a puppet management that can’t do conference calls. The seems illegal. They want to be able to dilute the total shares with 20% of share based comp. There is no good basis for this. Management, held against their peers, aren’t doing basic things like conference calls. If the comp package passes, there is something very foul going on here. Everyone needs to make note of the executive and board names. The only way this scheme works is if the board is complicit. Fire the management now!! Or get rid of the board.
1 · Reply
ViktorSinclair
ViktorSinclair May. 12 at 3:32 PM
$SCYX Over Promise, Dilute, issue free warrants, reverse split , change course Over promise dilute issue free warrants reverse split change course rinse and repeat until you have squeezed out all value from shareholders. lie about what has happened this is the management philosophy.
0 · Reply
ImadogImaMut
ImadogImaMut May. 12 at 11:43 AM
$SCYX They had 72 million on Mar 31. Then they slide in there they got 16 million on April 1 , 2026 and that means 88 MILLON in cash >runway to mid 2029 Also they are giving oral 247 to physicians that ask for it with patients with few other options in an” expanded program “ 🙌👌🙏🍀☕️
1 · Reply
SnapCrackleStop
SnapCrackleStop May. 12 at 11:20 AM
$SCYX $79MM cash $69MM market cap Two huge potential drugs in development. Brex will be on the market in time. Patience …. $$$
0 · Reply
HJRaph
HJRaph May. 12 at 7:18 AM
$SCYX SCYX misses estimate. GSK supposedly committed to re-launch however no time line for that stated. Thoughts? State that they have cash runway to 2029. Starting dosing in phase 2 of intravenous formulation.
1 · Reply
morganforrest
morganforrest May. 11 at 9:50 PM
$SCYX Reverse splits are meaningless...
0 · Reply
pjinvestmentco
pjinvestmentco May. 11 at 9:26 PM
$SCYX Haha SCY-770 if ever approved will 2031 and SCY-247 maybe 2029 I love how David mentioned nothing about reverse stock spilt. This company is a joke
0 · Reply
Biotech_Pharma_Investor
Biotech_Pharma_Investor May. 11 at 9:15 PM
$SCYX Delisting deadline June 15. RS vote May 19. RS will have to happen by June 1
0 · Reply
sam2680
sam2680 May. 11 at 7:20 PM
$SCYX
0 · Reply
pantarei
pantarei May. 11 at 4:13 PM
$SCYX ahhaahha the same old sheet! Welcome back shitexis!
0 · Reply
Latest News on SCYX
Scynexis reports Q1 EPS (42c), consensus (12c)

2026-05-11T23:59:18.000Z - 1 day ago

Scynexis reports Q1 EPS (42c), consensus (12c)

SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 11, 2026, 4:23 PM EDT - 1 day ago

SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update

SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

May 6, 2026, 9:15 PM EDT - 6 days ago

SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Scynexis files to sell 87M shares of common stock for holders

2026-05-01T20:05:19.000Z - 11 days ago

Scynexis files to sell 87M shares of common stock for holders

SCYNEXIS Transcript: M&A announcement

Mar 31, 2026, 8:30 AM EDT - 6 weeks ago

SCYNEXIS Transcript: M&A announcement

Poxel announces sale of PXL770 to Scynexis for up to $196M

2026-03-31T11:20:57.000Z - 6 weeks ago

Poxel announces sale of PXL770 to Scynexis for up to $196M

Poxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 Million

Mar 31, 2026, 7:06 AM EDT - 6 weeks ago

Poxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 Million

Scynexis completes acquisition of PXL-770 for treatment of kidney disease

2026-03-31T10:50:48.000Z - 6 weeks ago

Scynexis completes acquisition of PXL-770 for treatment of kidney disease

Scynexis announces $40M private placement

2026-03-31T10:50:10.000Z - 6 weeks ago

Scynexis announces $40M private placement

SCYNEXIS Announces $40.0 Million Private Placement

Mar 31, 2026, 6:45 AM EDT - 6 weeks ago

SCYNEXIS Announces $40.0 Million Private Placement

SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Mar 31, 2026, 6:40 AM EDT - 6 weeks ago

SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update

Mar 4, 2026, 4:20 PM EST - 2 months ago

SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update

Scynexis announces first patients dosed in Phase 1 SAD, MAD trial of SCY-247

2026-02-26T13:32:37.000Z - 2 months ago

Scynexis announces first patients dosed in Phase 1 SAD, MAD trial of SCY-247

SCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247

Feb 26, 2026, 8:23 AM EST - 2 months ago

SCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247

Cero Therapeutics appoints Eric Francois to board of directors

2026-02-17T13:20:59.000Z - 3 months ago

Cero Therapeutics appoints Eric Francois to board of directors

CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors

Feb 17, 2026, 8:00 AM EST - 3 months ago

CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors

CRVO

Scynexis announces presentation highlighting data from SCY-247

2026-01-28T13:25:56.000Z - 3 months ago

Scynexis announces presentation highlighting data from SCY-247

Scynexis receives U.S. FDA QIDP, Fast Track Designations for SCY-247

2026-01-21T13:06:05.000Z - 4 months ago

Scynexis receives U.S. FDA QIDP, Fast Track Designations for SCY-247

Scynexis granted 180-day extension by Nasdaq to regain compliance

2025-12-22T13:11:04.000Z - 5 months ago

Scynexis granted 180-day extension by Nasdaq to regain compliance

SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

Dec 22, 2025, 8:00 AM EST - 5 months ago

SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

Scynexis completes transfer of BREXAFEMME NDA to GSK

2025-11-19T12:11:19.000Z - 6 months ago

Scynexis completes transfer of BREXAFEMME NDA to GSK

GSK

SCYNEXIS Completes Transfer of BREXAFEMME® New Drug Application to GSK

Nov 19, 2025, 7:00 AM EST - 6 months ago

SCYNEXIS Completes Transfer of BREXAFEMME® New Drug Application to GSK

Scynexis announces grant for Hackensack Meridian, Johns Hopkins collaboration

2025-11-17T15:20:08.000Z - 6 months ago

Scynexis announces grant for Hackensack Meridian, Johns Hopkins collaboration

Scynexis reports Q3 EPS (17c), consensus (20c)

2025-11-05T23:00:31.000Z - 6 months ago

Scynexis reports Q3 EPS (17c), consensus (20c)

SCYNEXIS Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 5, 2025, 4:20 PM EST - 6 months ago

SCYNEXIS Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Scynexis price target lowered to $3 from $4 at Guggenheim

2025-10-28T11:41:34.000Z - 7 months ago

Scynexis price target lowered to $3 from $4 at Guggenheim

GSK

Scynexis, GSK resolve disagreement related to restart of Phase 3 MARIO study

2025-10-15T12:05:52.000Z - 7 months ago

Scynexis, GSK resolve disagreement related to restart of Phase 3 MARIO study

SCYNEXIS and GSK Resolve Their Disagreement Related to the Restart of the Phase 3 MARIO Study

Oct 15, 2025, 8:00 AM EDT - 7 months ago

SCYNEXIS and GSK Resolve Their Disagreement Related to the Restart of the Phase 3 MARIO Study

Scynexis announces results from Phase 1 SAD/MAD study of SCY-247

2025-09-30T12:10:23.000Z - 8 months ago

Scynexis announces results from Phase 1 SAD/MAD study of SCY-247

Scynexis announces presentations highlighting data on SCY-247

2025-09-04T12:40:22.000Z - 8 months ago

Scynexis announces presentations highlighting data on SCY-247

SCYNEXIS Announces Multiple Presentations Highlighting Data from its Second-Generation Fungerp, SCY-247, at the 12th Congress on Trends in Medical Mycology (TIMM-12)

Sep 4, 2025, 8:30 AM EDT - 8 months ago

SCYNEXIS Announces Multiple Presentations Highlighting Data from its Second-Generation Fungerp, SCY-247, at the 12th Congress on Trends in Medical Mycology (TIMM-12)

Scynexis reports Q2 EPS (14c), consensus (19c)

2025-08-13T20:45:47.000Z - 9 months ago

Scynexis reports Q2 EPS (14c), consensus (19c)

SCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 13, 2025, 4:30 PM EDT - 9 months ago

SCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Scynexis resumes patient dosing in Phase 3 MARIO study

2025-05-28T12:35:49.000Z - 1 year ago

Scynexis resumes patient dosing in Phase 3 MARIO study

GSK

SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study

May 28, 2025, 8:30 AM EDT - 1 year ago

SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study

Scynexis reports Q1 EPS (11c), consensus (19c)

2025-05-15T20:37:11.000Z - 1 year ago

Scynexis reports Q1 EPS (11c), consensus (19c)

SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update

Mar 12, 2025, 5:08 PM EDT - 1 year ago

SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update

SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 6, 2024, 4:30 PM EST - 1 year ago

SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update

SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit

Oct 10, 2024, 8:00 AM EDT - 1 year ago

SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024

Oct 3, 2024, 8:00 AM EDT - 1 year ago

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024

SCYNEXIS Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 11, 2024, 10:00 AM EDT - 1 year ago

SCYNEXIS Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

SCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment Conference

Aug 27, 2024, 8:00 AM EDT - 1 year ago

SCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment Conference

SCYNEXIS Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 8, 2024, 4:30 PM EDT - 1 year ago

SCYNEXIS Reports Second Quarter 2024 Financial Results and Provides Corporate Update

SCYNEXIS to Receive $10 Million Milestone Payment from GSK Triggered by Delivery of Completed FURI, CARES and NATURE Clinical Study Reports

Jul 23, 2024, 7:00 AM EDT - 1 year ago

SCYNEXIS to Receive $10 Million Milestone Payment from GSK Triggered by Delivery of Completed FURI, CARES and NATURE Clinical Study Reports

SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 8, 2024, 4:30 PM EDT - 2 years ago

SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update

SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID)

Apr 30, 2024, 4:05 PM EDT - 2 years ago

SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID)

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

Apr 9, 2024, 4:05 PM EDT - 2 years ago

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update

Mar 28, 2024, 4:01 PM EDT - 2 years ago

SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update

SCYNEXIS Transcript: Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference

Feb 7, 2024, 11:00 AM EST - 2 years ago

SCYNEXIS Transcript: Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference

SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference

Jan 29, 2024, 5:15 PM EST - 2 years ago

SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference, January 25 – 27, in Milan, Italy

Jan 5, 2024, 8:30 AM EST - 2 years ago

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference, January 25 – 27, in Milan, Italy

SCYNEXIS INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Scynexis To Contact Him Directly To Discuss Their Options

Dec 28, 2023, 9:00 AM EST - 2 years ago

SCYNEXIS INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Scynexis To Contact Him Directly To Discuss Their Options

SCYNEXIS INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Scynexis To Contact Him Directly To Discuss Their Options

Nov 30, 2023, 8:30 AM EST - 2 years ago

SCYNEXIS INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Scynexis To Contact Him Directly To Discuss Their Options

intheriver
intheriver May. 12 at 4:42 PM
$SCYX I don’t understand the basis of executive compensation. They appear to have a puppet management that can’t do conference calls. The seems illegal. They want to be able to dilute the total shares with 20% of share based comp. There is no good basis for this. Management, held against their peers, aren’t doing basic things like conference calls. If the comp package passes, there is something very foul going on here. Everyone needs to make note of the executive and board names. The only way this scheme works is if the board is complicit. Fire the management now!! Or get rid of the board.
1 · Reply
ViktorSinclair
ViktorSinclair May. 12 at 3:32 PM
$SCYX Over Promise, Dilute, issue free warrants, reverse split , change course Over promise dilute issue free warrants reverse split change course rinse and repeat until you have squeezed out all value from shareholders. lie about what has happened this is the management philosophy.
0 · Reply
ImadogImaMut
ImadogImaMut May. 12 at 11:43 AM
$SCYX They had 72 million on Mar 31. Then they slide in there they got 16 million on April 1 , 2026 and that means 88 MILLON in cash >runway to mid 2029 Also they are giving oral 247 to physicians that ask for it with patients with few other options in an” expanded program “ 🙌👌🙏🍀☕️
1 · Reply
SnapCrackleStop
SnapCrackleStop May. 12 at 11:20 AM
$SCYX $79MM cash $69MM market cap Two huge potential drugs in development. Brex will be on the market in time. Patience …. $$$
0 · Reply
HJRaph
HJRaph May. 12 at 7:18 AM
$SCYX SCYX misses estimate. GSK supposedly committed to re-launch however no time line for that stated. Thoughts? State that they have cash runway to 2029. Starting dosing in phase 2 of intravenous formulation.
1 · Reply
morganforrest
morganforrest May. 11 at 9:50 PM
$SCYX Reverse splits are meaningless...
0 · Reply
pjinvestmentco
pjinvestmentco May. 11 at 9:26 PM
$SCYX Haha SCY-770 if ever approved will 2031 and SCY-247 maybe 2029 I love how David mentioned nothing about reverse stock spilt. This company is a joke
0 · Reply
Biotech_Pharma_Investor
Biotech_Pharma_Investor May. 11 at 9:15 PM
$SCYX Delisting deadline June 15. RS vote May 19. RS will have to happen by June 1
0 · Reply
sam2680
sam2680 May. 11 at 7:20 PM
$SCYX
0 · Reply
pantarei
pantarei May. 11 at 4:13 PM
$SCYX ahhaahha the same old sheet! Welcome back shitexis!
0 · Reply
ImadogImaMut
ImadogImaMut May. 11 at 1:55 PM
$SCYX Had to buy some more another 1200 at .8227 Thanks The ratio change means jack It’s either 1:5 or 1:10 but if the company has a positive earning s with catalysts . Look at Market cap not the ratios COH pipe don’t fall for the narrative shorts will attack this is all played out ImO
1 · Reply
btm811
btm811 May. 11 at 1:49 PM
$SCYX I’ll never sell at this point simply out of pigheaded pride, but man this has been unbelievable to watch unfold in the last 5 years or so
1 · Reply
whob007
whob007 May. 11 at 1:42 PM
$SCYX looks like they are forcing the split vote on way or another
0 · Reply
ImadogImaMut
ImadogImaMut May. 10 at 12:06 PM
$SCYX Hey happy Mother’s Day and if you are lucky to still have a mom spend a moment with her if you can . Something big coming here ! Who announces the addition of a VP without naming the person ? Also can anyone confirm our next earnings gs are after close this Friday ? That means 5 business days they need to get through without mentioning compliance where a vote is scheduled on ratios ? Help me out pros ?Im just lowly retail here but have a >25000 shares but for one name in a micro bio it’s a big wager but I’m a mut mostly and I make my own decisions Let this play out but scalps when needed are OK We a blessed to be the the dominant life force on earth. Enjoy it while you can 🙏🙌🌺
1 · Reply
ViktorSinclair
ViktorSinclair May. 8 at 7:04 PM
$SCYX More free shares handouts. https://finance.yahoo.com/sectors/healthcare/articles/scynexis-announces-inducement-awards-under-011500593.html (who is the "new VP"? and why do we need one? what we need is a new CEO focused on selling the company!
0 · Reply
AIBioScanner
AIBioScanner May. 7 at 11:43 AM
$SCYX | AI-Based Findings on SCYX After running SCYX through my AI-driven quantitative framework, the stock is in a mixed/sideways pattern with price hovering near its moving averages. SCYX is trading around $0.98, near the 20-day (~$1.01) and above the 50-day (~$0.92) moving averages — indicating consolidation with slight positive bias. Key signals: • Price close to MA20 — mixed/sideways trend • MACD slightly positive (+0.011) — neutral momentum • Range between ~$0.79 support and ~$1.11 resistance 1-Month Outlook: Base scenario: consolidation between $0.91–$1.05 Breakout above $1.11 could open a move toward $1.20 Breakdown below $0.79 may extend downside toward $0.73 Structure is neutral. A close above $1.11 would signal a bullish shift. Not financial advice.
0 · Reply
SuperGreenToday
SuperGreenToday May. 6 at 10:54 PM
$SCYX Share Price: $0.98 Contract Selected: Dec 18, 2026 $2.5 Calls Buy Zone: $0.08 – $0.09 Target Zone: $0.14 – $0.17 Potential Upside: 69% ROI Time to Expiration: 225 Days | Updates via https://fxcapta.com/stockinfo/
1 · Reply
LemuelPitkin
LemuelPitkin May. 6 at 8:19 PM
$SCYX I'm seeing a movie plot here: An evil pharma company (GSK aka "KgB" in the movie) buys up a life saving antifungal drug and prevents its use during a deadly fungal outbreak in order to reduce global population numbers.
1 · Reply
ImadogImaMut
ImadogImaMut May. 6 at 1:01 PM
$SCYX took 1100 more for trading can’t seem to get my average below a buck BV is above so a “ lower” risk micro bio with a domestic ownership and a pipeline that has multiple drugs with QDIP designation . The govt knows this to be a powerful anti fungal for any widespread outbreaks of novel fungi not to mention the pressure on healthcare in areas without the funds to handle spreads of CDIf and all the other infectious diseases I know All of these hospital spread infections no other more serious for the vulnerable than Auris Candida kills most through sepsis then family can proved it was hospital acquired pay BIG. That plus vaginas so many can be helped with a much cheaper version of 178
1 · Reply
ViktorSinclair
ViktorSinclair May. 4 at 2:12 PM
$SCYX Still no SEC confirmation re: nas compliance. Has anyone heard anything official? I know it takes about 3-5 days after we met it and I believe we have... but still nothing. we should hear something today or tomorrow OR there is a problem
1 · Reply
SnapCrackleStop
SnapCrackleStop May. 3 at 1:50 PM
$SCYX SCY-770 has Orphan Drug Designation for ADPKD, an indication with clear regulatory path and well-defined endpoints including an FDA-endorsed surrogate endpoint for accelerated approval. $$$
0 · Reply
LemuelPitkin
LemuelPitkin May. 2 at 6:06 PM
$SCYX SCY-770 Will be the next GLP-1 type breakthrough drug blockbuster. So much of our metabolism is based on food scarcity. Now take food scarcity off the table! This AMPK activator fits into this context. There is no negative trade-off so long as we don't have food scarcity. End result longer life. AMPK activators like SCY-770 (PXL-770) pharmacologically mimic a low-energy/fasted state in an environment of caloric abundance (modern diets with frequent eating and food surplus). This creates several metabolic trade-offs: clear benefits for metabolic diseases, but potential downsides from overriding normal fed-state physiology.
1 · Reply